Volume 1.25 | Jul 6

Hematopoiesis News 1.25, July 6, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Reprogrammed Human Blood Cells Show Promise for Disease Research  ShareThis
Cells from frozen human blood samples can be reprogrammed to an embryonic-stem-cell-like state, according to researchers. [Press release from the Whitehead Institute discussing online prepublication in Cell Stem Cell]

MethoCult® Express: Request A Sample  
Enumerate total hematopoietic progenitors (CFC) in cord blood units in only 7 days with MethoCult® Express
by STEMCELL Technologies


Spit Test for Bone Marrow Matches
Currently blood samples are used to determine bone marrow type for potential matches, which means a trip to the doctors. Anthony Nolan Trust is launching a new way for people to join its register; they will ask for a saliva sample, which can be given from the comfort of your own home. [BBC News]

Drug Mitigates Toxic Effects of Radiation in Mice
A research team provides a first example of successful radiomitigation in mammals. [Press release from the University of North Carolina School of Medicine discussing online prepublication in Science]

CDC Team’s XMRV-Chronic Fatigue Syndrome Paper Is Out
Researchers looking at the blood of 51 people with chronic-fatigue syndrome and 56 healthy people found no association between the XMRV virus and the syndrome. [The Wall Street Journal]

Watch Procedure Now  
Further Improve Hematopoietic Progenitor Proliferation
with Human LDL
by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Reprogramming of Human Peripheral Blood Cells to Induced Pluripotent Stem Cells
Researchers derived induced pluripotent stem cells (iPSCs) from frozen human peripheral blood samples. Some of the iPSCs had rearrangements of the T cell receptor, indicating that T cells can be reprogrammed to pluripotency. [Cell Stem Cell]

Reprogramming of T Cells from Human Peripheral Blood
Here, researchers report the derivation of iPSCs from multiple human blood sources including peripheral blood mononuclear cells (PBMCs) harvested by routine venipuncture. [Cell Stem Cell]

Mitigation of Hematologic Radiation Toxicity in Mice Through Pharmacological Quiescence Induced by CDK4/6 Inhibition
Here, using selective and structurally distinct small molecule inhibitors of cyclin-dependent kinase 4 (CDK4) and CDK6, researchers have demonstrated that selective cellular quiescence increases radioresistance of human cell lines in vitro and mice in vivo. [J Clin Invest]

The Carboxyterminal EF-Domain of Erythroid Alpha Spectrin are Necessary for Optimal Spectrin-Actin Binding
The severely anemic sph(1J)/sph(1J) mouse has very fragile red cells and lacks the last 13 amino acids in the EF-domain, implying the domain is critical for skeletal integrity. To test this, researchers constructed a minispectrin heterodimer from the actin-binding domain, the EF-domain and four adjacent spectrin repeats in each chain. [Blood]

PTEN Gene” target=”_blank” href=”http://www.nature.com/leu/journal/vaop/ncurrent/full/leu2010145a.html” alias=”C06 Long-Term Exposure of Leukemia Cells to Multi-Targeted Tyrosine Kinase Inhibitor Induces Activations of AKT, ERK and STAT5 Signaling Via Epigenetic Silencing of the PTEN Gene” conversion=”false”>Long-Term Exposure of Leukemia Cells to Multi-Targeted Tyrosine Kinase Inhibitor Induces Activations of AKT, ERK and STAT5 Signaling Via Epigenetic Silencing of the PTEN Gene
Taken together, epigenetic silence of PTEN is one of the mechanisms that cause drug resistance in individuals with leukemia after exposure to imatinib. [ Leukemia]

Dichotomy in NF-(Kappa)B Signaling and Chemoresistance in Immunoglobulin Variable Heavy-Chain-Mutated Versus Unmutated CLL Cells Upon CD40/TLR9 Triggering
To juxtapose proliferative with antiapoptotic signals, researchers investigated the effects of CpG in the context of CD40 ligation in mutated versus unmutated chronic lymphocytic leukemia (CLL) cells in this study. [Oncogene]

Absence of Evidence of Xenotropic Murine Leukemia Virus-Related Virus Infection in Persons with Chronic Fatigue Syndrome and Healthy Controls in the United States
To investigate the association of XMRV with chronic fatigue syndrome (CFS) researchers tested blood specimens from 51 persons with CFS and 56 healthy persons from the U.S. for evidence of XMRV infection by using serologic and molecular assays. [ Retrovirology]


Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes
Human T cell lymphotropic virus type-I-associated adult T-cell leukemia/lymphoma (ATL) is an aggressive, chemotherapy-resistant malignancy. Researchers report a meta-analysis of antiviral therapy of ATL. [J Clin Oncol]

Allergenic Stem Cell Transplantation Provides Durable Disease Control in Poor-Risk Chronic Lymphocytic Leukemia: Long-Term Clinical and MRD Results of the GCLLSG CLL3X Trial
Allergenic stem cell transplantation for poor-risk chronic lymphocytic leukemia can result in long-term minimal residual disease (MRD)-negative survival in up to half of the patients independent of the underlying genomic risk profile. [Blood]


Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in both AML and MDS
Cyclacel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company’s sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia and myelodysplastic syndromes. [Cyclacel Pharmaceuticals, Inc. Press Release]

Sanofi-aventis to Acquire TargeGen Inc. 
Sanofi-aventis announced that it has signed an agreement for the acquisition of TargeGen Inc., a privately held U.S. biopharmaceutical company developing small molecule kinase inhibitors for the treatment of certain forms of leukemia, lymphoma and other hematological malignancies and blood disorders. [Sanofi-Aventis Press Release]

Tarix Pharmaceuticals’ TXA127 Receives FDA Orphan Drug Designation for Stem Cell Engraftment
Tarix Pharmaceuticals announced that it’s drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration as a treatment to enhance engraftment in patients receiving a stem cell transplant. [FierceBiotech Press Release]

Universities Bank on Stem-Cell Research
Bay Area universities and research groups are betting they can spawn a new generation of medical breakthroughs and the next growth engine for the region’s biotechnology industry. [The Wall Street Journal]


Research Budgets Face Austerity in 2012
The National Institutes of Health and other life sciences and biomedical research funding agencies will need to trim their budgets for 2012, which are to be planned over the summer, to satisfy a White House that is now stressing deficit reduction and belt-tightening after two years of stimulus funding-boosted research budgets. [The Office of Management and Budget, United States]

Strong Medicine for French Research
The medical-research adviser to France’s president aims to shift power and money to universities. [National Research Agency, France]

Meeting of the National Advisory Council for Healthcare Research and Quality [Agency for Healthcare Research and Quality, United States]

Maryland Stem Cell Research Commission – Public Meeting Notice [Maryland Stem Cell Research Commission, United States]

Center for Scientific Review; Notice of Closed Meetings [National Institutes of Health, United States]

Science Board Advisory Committee; Notice of Meeting (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]

Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics [Food and Drug Administration, United States]

Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications (Docket Nos. FDA-2010-M-0068, FDA-2010-M-0078, FDA-2010-M-0063, FDA-2010-M-0135, FDA-2010-M-0158) [Food and Drug Administration, United States]


Translational Cancer Medicine 2010 – USA
July 11-14, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

The European Molecular Biology Organization (EMBO) Meeting 2010
September 4-7, 2010
Barcelona, Spain

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Stem Cells and Regeneration
October 3-9, 2010
Woods Hole, United States

American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us